Content about Denmark

March 22, 2013
Novo Nordisk drug produces significant weight loss in study

A drug made by Novo Nordisk for Type 2 diabetes produced a 6% loss of weight in a trial of the drug in obese patients, the company said.

BAGSVÆRD, Denmark — A drug made by Novo Nordisk for Type 2 diabetes produced a 6% loss of weight in a trial of the drug in obese patients, the company said.

The Danish drug maker announced results of a 56-week phase-3 trial to investigate the potential of Victoza (liraglutide) to produce and maintain weight loss in overweight and obese patients with Type 2 diabetes.

March 6, 2013
CRN names six new members

The Council for Responsible Nutrition announced the addition of six new members, including voting members Evolva Nutrition and NutraGenesis and associate members American Nurse Practitioner Foundation, HFL Sport Science, Intertek Cantox and Loeb & Loeb.

WASHINGTON — The Council for Responsible Nutrition on Tuesday announced the addition of six new members, including voting members Evolva Nutrition and NutraGenesis and associate members American Nurse Practitioner Foundation, HFL Sport Science, Intertek Cantox and Loeb & Loeb.  

Evolva Nutrition recently acquired the rights to the resveratrol business formerly owned by Fluxome Science A/S in Denmark. NutraGenesis is a provider of proprietary, branded nutraceutical ingredients that are designed for the dietary supplement, food and beverage marketplaces.

February 11, 2013
FDA turns down two Novo Nordisk insulin products

The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

BAGSVÆRD, Denmark — The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

Novo Nordisk said it received complete response letters from the FDA for Tresiba (insulin degludec) and Ryzodeg (insulin degludec and insulin aspart). The FDA issues a complete response letter when it has finished reviewing an application for a drug, but determines that the application can't be approved in its current form.

December 5, 2012
Novo Nordisk to form first all-diabetes pro-cycling team

Drug maker Novo Nordisk is creating what it calls the world's first all-diabetes professional cycling team, the company said.

BAGSVÆRD, Denmark — Drug maker Novo Nordisk is creating what it calls the world's first all-diabetes professional cycling team, the company said.

The Danish pharmaceutical manufacturer announced plans to create Team Novo Nordisk, a global team with more than 100 cyclists, triathletes and runners, all of whom have diabetes.

November 9, 2012
FDA panel recommends approval for two Novo Nordisk insulin products

A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

BAGSVÆRD, Denmark — A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

Novo Nordisk said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had voted 8-to-4 in favor of approval for insulin degludec and a combination treatment containing insulin degludec and insulin aspart.

June 15, 2012
Endocrine Society study: Vitamin D with calcium improves mortality in elder women

A study recently published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism suggests that vitamin D — when taken with calcium — can reduce the rate of mortality in seniors, thereby providing a possible means of increasing life expectancy, the society reported Friday.

CHEVY CHASE, Md. — A study recently published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism suggests that vitamin D — when taken with calcium — can reduce the rate of mortality in seniors, thereby providing a possible means of increasing life expectancy, the society reported Friday.

December 16, 2011
Lego, Warner Bros. Consumer Products to launch construction sets based on 'Lord of the Rings,' 'The Hobbit'

A line of build-and-play construction sets based on the "Lord of the Rings" trilogy and the upcoming film "The Hobbit" is coming to retail.

BILLUND, Denmark, and BURBANK, Calif. — A line of build-and-play construction sets based on the "Lord of the Rings" trilogy and the upcoming film "The Hobbit" is coming to retail.

Lego and Warner Bros. Consumer Products said it will introduce the Lego The Lord of the Rings construction sets are slated for a global launch beginning in June 2012 in the United States, with Lego The Hobbit: An Unexpected Journey scheduled for release later in the year.

October 11, 2011
Novartis stays focused on shipping, developing vaccinations

A lot has been happening at Swiss drug maker Novartis in the realm of vaccines.


BAGSVAERD, Denmark — A lot has been happening at Swiss drug maker Novartis in the realm of vaccines.


In July, the company began early shipment of its flu vaccine, Fluvirin, in order to ensure that patients can receive the earliest possible protection against influenza. The drug maker plans to ship more than 30 million doses.


October 11, 2011
Novo Nordisk educates diabetics with e-books

Danish drug maker Novo Nordisk has launched a five-
volume series of e-books designed to help patients work with their healthcare providers to better manage their diabetes.


BAGSVAERD, Denmark — Danish drug maker Novo Nordisk has launched a five-
volume series of e-books designed to help patients work with their healthcare providers to better manage their diabetes.


The series is part of the Cornerstones4Care patient-support program launched earlier this year, and the books will be available at such e-book sites as iBooks, Reader Store, the Nook Book Store and Free-eBooks.net toward the end of this year.


August 25, 2011
Novo Nordisk to build new corporate HQ

Novo Nordisk is investing 1 billion Danish kroner ($193.9 million) into new office buildings in Bagsværd, Denmark.

BAGSVÆRD, Denmark — Novo Nordisk is investing 1 billion Danish kroner ($193.9 million) into two new office buildings in Bagsværd, Denmark.

The drug maker said the new premises will house Novo Nordisk’s top management, 1,100 administrative employees and a number of shared facilities.

June 6, 2011
Hypoglycemic events can disrupt work productivity for diabetics, survey finds

A new survey sponsored by drug maker Novo Nordisk, which polled Type 1 and Type 2 diabetes patients in the United States, United Kingdom, Germany and France, found that about 1-in-5 respondents regularly are unable to attend a full day of work due to disruption caused by episodes of dangerously low blood sugar, also known as hypoglycemic events.

COPENHAGEN, Denmark — A new survey sponsored by drug maker Novo Nordisk, which polled Type 1 and Type 2 diabetes patients in the United States, United Kingdom, Germany and France, found that about 1-in-5 respondents regularly are unable to attend a full day of work due to disruption caused by episodes of dangerously low blood sugar, also known as hypoglycemic events.

February 2, 2011
Victoza, NovoSeven drive Novo Nordisk's sales

A collection of relatively new products helped drive up sales and profits at Novo Nordisk, the Danish drug maker said Wednesday.

BAGSVÆRD, Denmark — A collection of relatively new products helped drive up sales and profits at Novo Nordisk, the Danish drug maker said Wednesday. 

Sales increased by 22% in the North American markets when measured in local currencies, and by 29% when measured in Danish kroner, the company said. Operating profits were $3.5 billion, a 16% increase over 2009.

January 4, 2011
Pfizer inks deal with Santaris

Pfizer will pay Danish biotech company Santaris Pharma $14 million for access to its development platform for RNA-based therapies, Pfizer said Tuesday.

SAN DIEGO — Pfizer will pay Danish biotech company Santaris Pharma $14 million for access to its development platform for RNA-based therapies, Pfizer said Tuesday.

The drug maker said the deal would expand on an existing one between Hoersholm, Denmark-based Santaris and Wyeth, which Pfizer acquired in 2009. Santaris could take in up to $600 million in milestone payments, as well as royalties on products developed under the collaboration.